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The reaction between cisplatin and DNA is conveniently 
studied using fluorescently labeled oligonucleotides and gel 
electrophoresis; as an example of application, the inhibition 
of this reaction by citrate is demonstrated, which might 10 
increase selectivity of cisplatin towards guanine over adenine. 
Cisplatin is one of the most successful and important anti-
cancer drugs.1-4  It is generally accepted that DNA is the 
molecular target of cisplatin, forming intrastrand crosslinked 
guanines,1 although the exact mechanism is still under 15 
debate.5 A lot has already been learned about the reaction 
between DNA and cisplatin.6 The difference in the Cl- 
concentration outside a cell (~100 mM) and inside (~4-12 
mM) might facilitate dissociation of Cl- and adding water 
inside the cell.1 The aquated product is trapped in the cell to 20 
react with various nucleophilic species including DNA.7,8 
Mechanisms related to electron transfer have also been 
proposed.9 Due to the lack of appropriate analytical tools to 
follow cisplatin inside live cells,5 most studies were carried 
out in simple buffers. The cellular environment, however, is 25 
much more complex containing numerous small molecules, 
nucleic acids and proteins that compete for cisplatin 
binding.10,11 The cisplatin concentration inside cells is 
estimated to be just nanomolar to low micromolar.5 Many 
cellular compounds can tightly bind to cisplatin, leaving little 30 
free cisplatin for DNA binding. Examples of such competitors 
include sulfer containing proteins,12,13 glutathione (GSH),14,15 
and even inorganic anions.16 Before cisplatin can react with 
DNA, it has to be released from these competing ligands.17  
 Many inorganic ions have a high cellular concentration and 35 
may affect cisplatin binding to DNA. For example, phosphate, 
acetate, and carbonate have been shown to bind to 
cisplatin.16,18-21 Citrate is an important cellular metabolite but 
its effect on cisplatin has not been studied. Cellular citrate 
concentration is high in Aspergillus niger (~2-30 mM),22 and 40 
in Saccharomyces cerevisiae (~3 mM).23,24 In human tissues, 
citrate was reported to be 0.2–0.45 mM.25 This is likely to be 
under-estimated since most citrate resides in mitochondria, 
where it is formed and utilized to make lipids.26 It has also 
been suggested that the real target of cisplatin might be the 45 
mitochondria DNA instead of the nuclear DNA,27 where the 
role of citrate is even more relevant. Therefore, we are 
interested in studying the effect of citrate on the reaction 
between cisplatin and DNA. 
 Cisplatin binding to DNA has been monitored using 50 
HPLC,28,29 NMR,30 electrochemistry,31 mass spectrometry,32 
and elemental analysis.33 Compared to these methods, gel 
electrophoresis is more cost-effective and readily accessible to 
many researchers. It can tolerate complex sample matrix 
without worrying about clotting of column or spectroscopic 55 
interference. Gel electrophoresis has been used to confirm 
DNA binding by cisplatin in a few reports,16,28,34 where most 
employed radioisotope labels or DNA staining dyes for 
imaging long biolgical DNA. Given the development and 
recent applications of covalent fluorophore labels, such 60 
advances have not been widely applied to study 
DNA/cisplatin reaction.35 Herein, we use gel electrophoresis 
to follow this reaction in citrate buffer. 
 FAM (carboxyfluorescein)-labeled DNAs are popular 
probes because of their low cost and high quantum yield. As 65 
an initial test, we employed FAM-labeled 15-mer DNA 
homopolymers. The DNAs were mixed with increasing 
concentrations of cisplain for 16 h and the samples were then 
loaded into a non-denaturing polyacrylamide gel. A gradual 
shift of the FAM-A15 band with reduced mobility was 70 
observed with increasing cisplatin concentration (Figure 1A), 
suggesting reaction between this DNA and cisplatin. The Pt-
DNA adduct did not migrate as a single band, suggesting the 
presence of a broad range of products, possibly due to 
different levels and positions of platination. Fluorescence 75 
quenching was also observed, especially at high Pt 
concentrations. On the other hand, no shift was observed with 
FAM-T15 and its fluorescence just dropped in intensity with 
increasing cisplatin concentration (Figure 1B). Reactions also 
occurred with FAM-C15 and its product distribution pattern 80 
was quite different, where discrete bands were observed at 
low Pt concentrations and the gel smeared at high Pt 
concentrations (Figure 1C). Finally, FAM-G15 showed slightly 
smeared gel even for the initial free DNA, possibly due to its 
tendency to form various secondary structures such as inter- 85 
and intra-molecular quadruplexes (Figure 1D). Mass spectrum 
of FAM-G15 showed a few high molecular weight species, 
consistent with the smeared gel (Figure S1, ESI). Addition of 
cisplatin produced a clear shift, consistent with the fact that 
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cisplatin has high affinity toward guanine.  
 This initial test suggests that FAM-labeled DNA and gel 
electrophoresis can be used to study DNA reaction with 
cisplatin but fluorescence quenching needs to be suppressed. 
We next tested Alexa Fluor 647 (AF) labeled T15, since AF is 5 
known to be a more stable fluorophore. We chose T15 for its 
low reactivity with cisplatin and fluorescence intensity can be 
directly compared. Using a short incubation time of 2 h, ~20% 
qenching was observed with FAM, while AF was not 
significantly quenched (Figure 2A). It needs to be noted that 10 
longer incubation can also quench AF, but to a less extent 
than FAM quenching. Therefore, we chose to use AF-labeled 
DNA for subsequent studies. 
 
 15 
Figure 1. Gel images of FAM-labeled A15 (A), T15 (B), C15 (C) and G15 (D) 
after reacting with various concentrations of cisplatin in water. The DNA 
concentrations are 0.5 M and the numbers marked on each lane are the 
molar ratio between cisplatin and DNA.  
 First, the cisplatin concentration-dependent study was 20 
repeated, where AF-A15 still showed  a similar mobility shift 
but the overall fluorescence intensity was stronger (Figure 
2B). On the other hand, no reaction took place with AF-T15 as 
expected and the band intensity was quite consistent (Figure 
2C). Next a time-dependent study was performed with AF-25 
A15. It is clear that the bands shifted to lower mobility over 
time (Figure 2D). We quantified the relative mobility shift by 
measuring the center of each band and obtained a reaction rate 
of 0.36 h-1 between cisplatin and AF-A15 (Figure S2). This 
rate is comparable with the literature reports.16  30 
 After optimizing the assay conditions, we next studied the 
reaction in citrate buffers using AF-A15. First, 0.25 mM 
cisplatin was mixed with various concentrations of citrate for 
24 h to allow complex formation. Then AF-A15 was added and 
incubated for another 16 h. In Figure 2E, the first lane on the 35 
left is the free DNA without cisplatin. All the other lanes 
contained cisplatin and the citrate concentration was gradually 
decreased. We observed a gradual mobility shift, which can be 
pictured as an inhibition curve and the middle point is ~0.5 
mM citrate. Since the Pt concentration was 0.25 mM, the 40 
inhibition effect by citrate is close to quantitative. Strong free 
DNA bands were observed with 5 mM citrate, where no 
cisplatin/DNA adduct was detected. Since cisplatin binding to 
DNA is thermodynamically stronger than to most other 
ligands,17 inhibit was incomplete at low citrate concentrations. 45 
After reacting with citrate, negatively charged complexes are 
formed, which might be a kinetic reason to disfavor the 
reaction with negatively charged DNA. 
 
 50 
Figure 2. (A) Gel images of FAM and AF-labeled T15 and after cisplatin 
treatment for 2 h. The structures of these two fluorophores are also shown. 
Gel images of AF-A15 (B), and AF-T15 (C) after reacting with various 
concentrations of cisplatin. The DNA concentrations are 0.5 M and the 
numbers marked on each lane are the molar ratio between cisplatin and 55 
DNA. (D) Gel images of AF-A15 after incubating with cisplatin for 
various time. Cisplatin concentration = 250 M. (E) Gel image of AF-A15 
incubated with various concentrations of citrate (pH 7) for 24 h and then 
incubated with cisplatin for another 16 h.  
 Different organelles inside a cell have different pH values. 60 
For example, endosomes and lysosomes are acidic and cancer 
tissues usually also have lower pH.36 The pH-dependent study 
is convenient to carry out with citrate since it can be used as a 
buffer over a wide pH range. Moderate DNA binding to 
cisplatin was observed only at pH 3 (Figure 3A), while 65 
binding was completely inhibited at higher pH. This might be 
related to the protonation of citrate at pH 3, thus suppressing 
its binding to cisplatin (the pKa values of citrate are 3.14, 4.75 
and 6.39). Overall, citrate is a strong inhibitor of cisplatin 
binding to poly-A DNA over a wide pH range.  70 
 In addition to cisplatin, a few other Pt-based drugs have 
also been approved for clinical use such as oxaliplatin and 
carboplatin. Next we studied their reaction with DNA in 
citrate (Figure 3B). Interestingly, we only observed reaction 
with cisplatin while no binding was detected with other Pt 75 
complexes in 16 h. A moderate reaction with carboplatin was 
observed only after 48 h (Figure S3). The main difference 
between cisplatin and carboplatin or oxaliplatin is that the two 
chloride ligands are replaced by two chelating carboxyl 
groups. The chloride leaving groups in cisplatin are liable 80 
compared to carboxyl leaving groups, which are moderately 
stable (Figure 3C). Therefore, cisplatin can be hydrolyzed and 
then react with citrate, while carboplatin or oxaliplatin does 
not react with citrate as readily. Mass spectrometry shows the 
presence of both mono-coordinated and chelated products 85 
between citrate and cisplatin (Figure S4).  
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 The above studies mainly used A15 DNA since it forms 
discrete bands in gel while the G15 products smeared more. It 
needs to be noted that the inhibition effect is less significant 
for G15 (Figure S5). An important advantage of fluorescence 
is multiplexed detection. With two different fluorophores, we 5 
next tested the effect of citrate in reaction selectivity between 
adenine and guanine. In the absence of citrate, both FAM-G15 
and AF-A15 reacted and the mobility decreased with time 
(Figure 3D, E, F). In the presence of citrate, AF-A15 was 
completely inhibited as expected (Figure 3G), while FAM-G15 10 
still reacted (Figure 3H), although slower than that in the 
absence of citrate. The merged band changed from orange to 
red after 4 h (Figure 3I), suggesting platination of FAM-G15. 
Therefore, an interesting effect of citrate is to increase the 
selectivity of cisplatin towards guanine compared to adenine, 15 
which might have implications for guanine being the eventual 
target of cisplatin.37-39  
 
 
Figure 3. (A) Inhibition of cisplatin binding to AF-A15 as a function of 20 
pH in citrate. (B) Reaction of platinum-based compounds with AF-A15 in 
the presence or absence of 10 mM citrate (denoted by the ‘+’ and ‘-’ 
signs). For all the gels, the first lane on the left is the free DNA without 
cisplatin. (C) Structures of the platinum drugs and citrate. Mixture of AF-
A15 and FAM-G15 with cisplatin imaged with the AF channel (D, G), the 25 
FAM channel (E, H) and the merged (F, I) in the absence of citrate (E-F) 
or in the presence of 10 mM citrate (G-I) as a function of time. 
 In summary, we employed fluorescently-labeled 
oligonucleotides for studying the reaction between cisplatin 
and DNA. Important reaction information such as product 30 
distribution, kinetics, and stoichiometry can all be obtained 
with this simple method. We further showed that citrate is an 
inhibitor for this reaction but can increase selectivity toward 
guanine over adenine. 
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